Value Microcaps Motherboard

[Bobwins]

VPHM knew that if they were successful, vancocin would attract generic wannabes. They researched the possibility thoroughly before buying Vancocin. In consulting with experts including former FDA staff, they concluded that full scale trials would be necessary for anyone wanting to make a generic oral vancocin. The hurdles involved are very expensive and take time. Since generics have plenty of bigger targets that can be approved in much less time, Vphm mgmt concluded that a generic was very unlikely to be tried.

The total annual sales of Vancocin have improved significantly to 120 million per year. However this is peanuts for most generics. They want bigger markets.

If someone was going to risk taking 4.5 to 5 years to go thru the process of making a generic vancocin, they would want a bigger prize at the end of the rainbow besides a small anti infective antibiotic with a 120 million annual sales. The cost of the trials would be a lot more than 120 million.

Vphm mgmt is not surprised by the issue. I'm sure that the surprise success of Vancocin due to the emergence of the nasty bug caused this interest. Remains to be seen whether Akorn is actually talking about Vancocin.

Bobwins